Obesity
By FormBlends Medical Team · Last reviewed April 2026
Obesity is a chronic metabolic disease defined by a BMI of 30 or higher, characterized by excess adipose tissue that increases the risk of numerous health conditions. It affects over 42% of US adults and is driven by a complex interaction of genetics, hormones, behavior, and environment. GLP-1 receptor agonists have transformed obesity treatment by producing clinically significant weight loss in large-scale trials.
Affects over 42% of US adults
FormBlends Condition Context
Reviewed May 14, 2026Treat Obesity condition guide as context for a safer next conversation. It should help with connect symptoms and treatment options to a safer provider conversation, while keeping the reader focused on condition-specific care, evidence limits, provider oversight, and the difference between general information and personal medical advice.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Common Symptoms
- BMI of 30 or greater
- Excess visceral and subcutaneous fat accumulation
- Shortness of breath during moderate activity
- Joint pain from excess mechanical load
- Elevated blood pressure and cholesterol
- Insulin resistance and prediabetic markers
- Sleep apnea and snoring
Common Causes
- Caloric surplus sustained over months or years
- Hormonal dysregulation including leptin resistance and low GLP-1 signaling
- Genetic factors affecting appetite regulation and fat storage
- Sedentary lifestyle with minimal energy expenditure
- Highly processed food environment promoting overconsumption
Treatment Options
Semaglutide
Semaglutide demonstrated 14.9% average body weight reduction in the STEP 1 trial, with 86% of participants losing at least 5% of body weight over 68 weeks.
Learn more about Semaglutide →Tirzepatide
Tirzepatide produced up to 22.5% weight loss in the SURMOUNT-1 trial at the highest dose, making it the most effective medication for obesity studied to date.
Learn more about Tirzepatide →AOD-9604
AOD-9604 is a modified fragment of human growth hormone studied for its lipolytic effects, targeting fat metabolism without the growth-promoting side effects of full GH.
Learn more about AOD-9604 →Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor studied for appetite suppression and increased energy expenditure in clinical obesity trials.
Learn more about Tesofensine →Find Treatment for Obesity
Browse clinics near you that treat obesity.
Find Clinics